Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2247-2258

  Quidville, Virginie ^a,b,c   Alsafadi, Samar ^a,b,c   Goubar, Aïcha ^a,b,c   Commo, Frederic ^a,b,c   Scott, Veronique ^a,b,c   Pioche Durieu, Catherine ^b,c   Girault, Isabelle ^a,b,c   Baconnais, Sonia ^b,c   Le Cam, Eric ^b,c   Lazar, Vladimir ^b,c   Delaloge, Suzette ^a,b   Saghatchian, Mahasti ^a,b   Pautier, Patricia ^b   Morice, Philippe ^b,c   Dessen, Philippe ^b,c   Vagner, Stephan ^a,b,c   Andre, Fabrice ^a,b,c  

^a Universite Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; SMALL INTERFERING RNA;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; SPLICEOSOME;

EID: 84876007868     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2501     Document Type: Article

References (39)

1. Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009;10:381-90.
2. Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 2003;12:5-14.
3. Zhou Z, Licklider LJ, Gygi SP, Reed R. Comprehensive proteomic analysis of the human spliceosome. Nature 2002;419:182-5.
4. Salgado-Garrido J, Bragado-Nilsson E, Kandels-Lewis S, Seraphin B. Sm and Sm-like proteins assemble in two related complexes of deep evolutionary origin. EMBO J 1999;18:3451-62.
5. Hermann H, Fabrizio P, Raker VA, Foulaki K, Hornig H, Brahms H, et al. snRNP Sm proteins share two evolutionarily conserved sequence motifs which are involved in Sm protein-protein interactions. EMBO J 1995;14:2076-88.
6. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009;136:701-18.
7. Dutertre M, Vagner S, Auboeuf D. Alternative splicing and breast cancer. RNA Biol 2010;7:403-11.
8. Pettigrew CA, Brown MA. Pre-mRNA splicing aberrations and cancer. Front Biosci 2008;13:1090-105.
9. Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 2008;1:37-42.
10. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8:349-57.
11. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007;39:1432-49.
12. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006;119:2635-41.
13. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378-86.
14. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005;42:342-57.
15. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004;37:584-94.
16. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9.
17. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-506.
18. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53-7.
19. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47-52.
20. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010;24:2343-64.
21. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005;19:1-13.
22. Baker KE, Parker R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. Curr Opin Cell Biol 2004;16:293-9.
23. Maquat LE. Nonsense-mediated mRNA decay. Curr Biol 2002;12: R196-7.
24. Lareau LF, Brooks AN, Soergel DA, Meng Q, Brenner SE. The coupling of alternative splicing and nonsense-mediated mRNA decay. Adv Exp Med Biol 2007;623:190-211.
25. Traganos F, Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol 1994;41:185-94.
26. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008;3: e1651.
27. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19: 5720-8.
28. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010;221:117-24.
29. Saltzman AL, Pan Q, Blencowe BJ. Regulation of alternative splicing by the core spliceosomal machinery. Genes Dev 2011;25:373-84.
30. Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol 2003;163: 1781-90.
31. Niu HT, Yang CM, Chen B, Dong Q. Biomarker research and some deduction in superficial bladder cancer cells combined with corresponding stroma. Cancer Biomark 2011;10:109-16.
32. Huot ME, Vogel G, Zabarauskas A, Ngo CT, Coulombe-Huntington J, Majewski J, et al. The Sam 68STARRNA-binding proteinr egulatesm TOR alternative splicing during adipogenesis. Mol Cell 2012;46:187-99.
33. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010;584:1287-95.
34. Lindquist RA, Ottina KA, Wheeler DB, Hsu PP, Thoreen CC, Guertin DA, et al. Genome-scale RNAi on living-cell microarrays identifies novel regulators of Drosophila melanogaster TORC1-S6K pathway signaling. Genome Res 2011;21:433-46.
35. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, et al. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc Natl Acad Sci U S A 2005;102:8764-9.
36. Iwata M, Ozawa Y, Uenaka T, Shimizu H, Niijima J, et al. E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts. Proc AmAssoc Cancer Res 2004;45. Abstract nr 2989.
37. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, et al. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. Invitro and in vivo antitumor activities. J Antibiot (Tokyo) 2004;57:188-96.
38. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007;3:576-83.
39. Ghosh G, Adams JA. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 2011;278:587-97.